IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL5.94▲ 0.11% USD/MXN19.06▼ 0.12% USD/CLP1,016▼ 0.06% USD/COP3,415▲ 1.73% USD/PEN3.44▼ 0.14% USD/ARS1,568▲ 0.20% USD/UYU40.61▲ 3.16% USD/PYG6,212▲ 2.34% USD/BOB11.64▲ 2.55% USD/DOP59.71▼ 0.48% USD/CRC441.73▲ 2.68% USD/GTQ7.64▲ 3.22% USD/HNL26.89▲ 3.31% USD/NIO36.62▲ 0.34% USD/VES913.46▼ 0.35% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.60% USD/TTD6.70▲ 2.00% EUR/BRL6.53▲ 1.21% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74% IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL 5.94 ▲ 0.01% USD/MXN 19.06 ▼ 0.13% USD/CLP 1,016 ▼ 0.09% USD/COP 3,428 ▲ 2.10% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,565 ▲ 0.01% USD/UYU 40.61 ▲ 3.16% USD/PYG 6,212 ▲ 2.34% USD/BOB 11.64 ▲ 3.02% USD/DOP 59.52 ▼ 0.80% USD/CRC 441.73 ▲ 2.68% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.89 ▲ 3.31% USD/NIO 36.62 ▲ 0.34% USD/VES 913.46 ▼ 0.45% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 2.60% USD/TTD 6.70 ▲ 2.00% EUR/BRL 6.52 ▲ 1.16% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74%
since 2009
Friday, November 20, 2026

Brazil Brazil Tax reform

Private Clinics in Brazil Negotiate Purchase of Five Million Indian Covid Vaccine Doses

By · · 4 min read
The immunizer is in Phase 3 trials in India and is dependent on ANVISA approval to be administered in Brazil. The agency finds no obstacle in the private network application.
The immunizer is in Phase 3 trials in India and is dependent on ANVISA approval to be administered in Brazil. The agency finds no obstacle in the private network application.

RIO DE JANEIRO, BRAZIL – The immunizer is in Phase 3 trials in India and is dependent on ANVISA approval to be administered in Brazil. The agency finds no obstacle in the private network application.

The most optimistic scenario estimates that the vaccine will be available in the Brazilian private network in March.

RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The Brazilian Association of Vaccination Clinics (ABCVAC) reported on Sunday, January 3rd, that it is negotiating with India’s Bharat Biotech laboratory the purchase of five million doses of a vaccine against Covid-19.

The immunizer, called Covaxin, had its emergency use in India approved by the country’s authorities on Sunday and is still subject to authorization by the National Health Regulatory  Agency (ANVISA) to be administered in Brazil.

The vaccine is in Phase 3 trials in India, a stage in which efficacy is examined. The first clinical trials showed that the immunizer does not cause serious side effects and produces antibodies for Covid-19.

According to ABCVAC chairman Geraldo Barbosa, the results of Phase 3 trials are expected to come out later this month. Should this be the case, the laboratory is expected to submit a request for final registration with ANVISA in February.

According to him, in an optimistic scenario, the vaccine should be available in private clinics in Brazil in the second half of March.

ANVISA reported that the emergency use authorization is temporary and prioritizes the public network. However, it stated that there is no impediment for a laboratory to also apply for emergency use to sell the vaccine to the private network. Nevertheless, this particular authorization must be requested.

In cases where a final registration is granted, use is approved in Brazil in general and the authorization will automatically apply to both the public and private networks.

Although the laboratory intends to apply for the final direct registration, Barbosa explained that the association has sent a letter to ANVISA regarding the option of extending the emergency registration, if granted, to the private network.

“If we secure this extension, we will be able to assist with vaccination coverage faster because the government must comply with the priority list it has defined. Because we understand that the vaccine is the same, the safety is the same. It would only be a bureaucratic matter, but we understand and respect the legislation,” he said.

Barbosa explained that the sale of vaccines to the private market will not impact the immunizer’s supply to the public network, given that the doses are part of an additional production by the laboratory.

“We have been looking for solutions for the private market and the option of this Indian vaccine has emerged, which is very promising. As the whole market was already committed to the government’s demands – and rightly so, because I believe it must be a priority – we tried an alternative solution. And this Indian company made itself available to offer part of its production to the Brazilian private market. So, it is an additional sale that will not interfere on the quantity that the government requested”, said the association’s chairman.

He stated that a memorandum of intent has already been signed between ABCVAC and the laboratory expressing interest in the purchase of vaccines. On Monday, January 4th, association representatives will fly to India to visit the laboratory, to check production capacity, and to proceed with the purchase negotiations.

“We are taking all precautions to overcome all health obstacles that are mandatory. Therefore, we don’t want to raise expectations, but we will have a vaccine for the private market in line with our prospects,” he said.

Still according to the chairman, data on the Covaxin have been in the process of ongoing submission to ANVISA for approximately 40 days.

Typically, all data on an immunizer are submitted and analyzed jointly, at the end of the process. However, faced with the Covid pandemic, ANVISA has implemented a new process in which data are submitted as soon as available in order to speed up its evaluation.

For the full picture, see our Brazil Tax Reform: Complete Guide.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.